Frontiers in Immunology, 2023 BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Yating Dian +2 more
exaly +3 more sources
Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]
BMJ OpenObjectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang +14 more
doaj +2 more sources
Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study [PDF]
Scientific ReportsHypertension is widely acknowledged as a major risk factor for disease severity and death in patients with coronavirus disease 2019 (COVID-19). Azvudine is recommended for COVID-19 patients in China.
Yu Chen +14 more
doaj +2 more sources
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context [PDF]
EClinicalMedicine, 2023 Summary: Background: As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions.
Yuming Sun +6 more
doaj +2 more sources
Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases [PDF]
Virology JournalBackground Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown.
Guanyue Su +14 more
doaj +2 more sources
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study [PDF]
Infectious Diseases and Therapy, 2023 Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao +17 more
doaj +2 more sources
Advanced ScienceCOVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and
Liu Wu
exaly +2 more sources
Azvudine for the treatment of cancer patients with COVID-19: a multicenter, real-world, retrospective, cohort study [PDF]
BMC CancerBackground Cancer patients are at an elevated risk for SARS-CoV-2 infection and require vigilant monitoring. The efficacy and safety of Azvudine in treating COVID-19 among this vulnerable group remain under-researched. Methods We conducted a multicenter,
Lei Li +13 more
doaj +2 more sources
A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes [PDF]
Frontiers in EndocrinologyIntroductionDuring the Omicron infection wave, diabetic patients are susceptible to COVID-19, which is linked to a poor prognosis. However, research on the real-world effectiveness and safety of Azvudine, a common medication for COVID-19, is insufficient
Yongjian Zhou +14 more
doaj +2 more sources
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study [PDF]
BMC Infectious DiseasesBackground Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients.
Zhiguo Zhou +5 more
doaj +2 more sources